• 08.01.2020 – 14:00

  Debiopharm International SA

  Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada

  MONTREAL, CANADA and LAUSANNE, SWITZERLAND (ots) - Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm, a swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada. ...

  more

• 30.09.2019 – 10:00

  Debiopharm International SA

  Debiopharm's novel IAP antagonist Debio 1143 achieves outstanding Phase II results for high-risk Head and Neck cancer patients

  Lausanne (ots) - Late breaking abstract results presented today at ESMO with chemo-radio sensitizer Debio 1143 present a promising breakthrough strategy to improve the front-line treatment of H&N cancer patients Debiopharm, a Swiss-based global biopharmaceutical company, presented today, at the ESMO Congress ...

  more

• 09.07.2019 – 09:00

  Debiopharm International SA

  Debiopharm and BIOASTER join forces to expand research to combat infectious diseases

  Lausanne, Switzerland and Lyon, France (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, and BIOASTER (www.bioaster.org), the French Technology Research Institute in infectiology and microbiology, announced today having officialized a broad research agreement for the development of diagnostic and management innovation for infectious diseases. ...

  more